These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10804921)

  • 1. Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy.
    Zimran A; Abrahamov A; Elstein D
    Isr Med Assoc J; 2000 Feb; 2(2):80-1. PubMed ID: 10804921
    [No Abstract]   [Full Text] [Related]  

  • 2. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
    Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
    Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation abnormalities in type 1 Gaucher disease in children.
    Deghady A; Marzouk I; El-Shayeb A; Wali Y
    Pediatr Hematol Oncol; 2006; 23(5):411-7. PubMed ID: 16728361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaucher disease: lessons from a decade of therapy.
    Grabowski GA
    J Pediatr; 2004 May; 144(5 Suppl):S15-9. PubMed ID: 15126979
    [No Abstract]   [Full Text] [Related]  

  • 5. Enzyme replacement therapy in a child with Gaucher disease.
    Masood Y; Ali AS
    J Coll Physicians Surg Pak; 2006 Dec; 16(12):786-8. PubMed ID: 17125641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New perspectives in type 2 Gaucher disease.
    Sidransky E
    Adv Pediatr; 1997; 44():73-107. PubMed ID: 9265968
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
    Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy.
    de Fost M; van Noesel CJ; Aerts JM; Maas M; Pöll RG; Hollak CE
    Haematologica; 2008 Jul; 93(7):1119-20. PubMed ID: 18519519
    [No Abstract]   [Full Text] [Related]  

  • 9. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
    Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.
    Burrow TA; Cohen MB; Bokulic R; Deutsch G; Choudhary A; Falcone RA; Grabowski GA
    J Pediatr; 2007 Feb; 150(2):202-6. PubMed ID: 17236903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease.
    Erikson A; Aström M; Månsson JE
    Neuropediatrics; 1995 Aug; 26(4):203-7. PubMed ID: 8544959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gaucher disease].
    Timonen T; Möttönen M; Nousiainen T; Herva R; Savolainen ER
    Duodecim; 2005; 121(19):2068-76. PubMed ID: 16300295
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT).
    Giona F; Palumbo G; Amendola A; Santoro C; Mazzuconi MG
    J Thromb Haemost; 2006 Aug; 4(8):1831-3. PubMed ID: 16879228
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination.
    Kattamis CA; Kattamis AC
    Semin Hematol; 1995 Oct; 32(4):269-79. PubMed ID: 8560284
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzyme replacement in Gaucher disease.
    Beutler E
    PLoS Med; 2004 Nov; 1(2):e21. PubMed ID: 15578103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
    J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
    Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do we treat patients with inflammatory bowel disease in adolescence?
    Taminiau JA; Delemarre HA
    Neth J Med; 1996 Feb; 48(2):57-9. PubMed ID: 8819800
    [No Abstract]   [Full Text] [Related]  

  • 19. [Organization of Gaucher disease management in France].
    Stirnemann J; de Villemeur TB; Belmatoug N
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S198-201. PubMed ID: 18228688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy.
    Langeveld M; de Fost M; Aerts JM; Sauerwein HP; Hollak CE
    Blood Cells Mol Dis; 2008; 40(3):428-32. PubMed ID: 17950007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.